Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
18,18 USD | +1,11 % | -1,73 % | -5,02 % |
27/02 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 | |
27/02 | Myriad Genetics, Inc. proporciona una previsión de ingresos para el primer trimestre de 2024 | CI |
Resumen de negocios
Número de empleados: 2 700
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Hereditary Cancers
43,5
%
| 306 | 45,0 % | 328 | 43,5 % | +7,30 % |
Prenatal
20,1
%
| 116 | 17,2 % | 151 | 20,1 % | +29,98 % |
Pharmacogenomics
18,4
%
| 128 | 18,8 % | 139 | 18,4 % | +8,54 % |
Tumor Profiling
18,0
%
| 129 | 19,0 % | 136 | 18,0 % | +5,44 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
89,2
%
| 592 | 87,2 % | 672 | 89,2 % | +13,56 % |
Rest of World
10,8
%
| 87 | 12,8 % | 82 | 10,8 % | -6,21 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 13/08/20 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | 29/01 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/04/14 |
Thomas P. Slavin
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/20 |
Kevin Haas
CTO | Chief Tech/Sci/R&D Officer | 38 | 01/08/18 |
Samraat Raha
COO | Chief Operating Officer | 52 | 11/12 |
Glenn Farrell
IRO | Public Communications Contact | - | 19/12/22 |
Matthew Scalo
IRC | Investor Relations Contact | - | 01/08/22 |
John Oberg
PRN | Corporate Officer/Principal | - | 03/01/23 |
Natalie Munk
AUD | Comptroller/Controller/Auditor | 43 | 01/07/20 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 16/09/09 |
Paul Bisaro
BRD | Director/Board Member | 63 | 31/10/22 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 27/05/20 |
Paul Diaz
CEO | Chief Executive Officer | 61 | 13/08/20 |
Lee Newcomer
BRD | Director/Board Member | 71 | 25/09/19 |
Colleen Reitan
BRD | Director/Board Member | 64 | 25/09/19 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 10/06/10 |
Director/Board Member | 50 | 21/07/20 | |
Rashmi Kumar
BRD | Director/Board Member | 53 | 10/09/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 90 478 255 | 88 355 484 ( 97,65 %) | 0 | 97,65 % |
Información de la empresa
Sector
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-5,02 % | 1644,89 M | |
+0,89 % | 12,8 mil M | |
-10,29 % | 7606,28 M | |
+1,78 % | 5406,54 M | |
-1,16 % | 4514,24 M | |
+5,74 % | 4494,23 M | |
-50,70 % | 3287,8 M | |
+12,21 % | 2732,23 M | |
-16,13 % | 2016,57 M | |
-11,50 % | 1725,91 M |
- Bolsa de valores
- Acciones
- Acción MYGN
- Empresa Myriad Genetics, Inc.